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IL-1 is a family ofcloselyrelated proteins deeply involved inthedevelopment and
maintenance of the inflammatory response. In fact, IL-1 appears identical to the
endogenous pyrogen responsible for the increase in basal temperature after infec-
tious events (1, 2); it provokes the changes in plasma levels ofdivalent cations and
acute-phase proteins typical of the inflammatory condition (1, 2); it is involved in
the alteration of corticosterone levels and ofglucose homeostasis (3, 4) and in the
catabolic processes associated with infection (1, 2); it induces neutrophilia and the
release ofprostaglandins and proteases in different cells (1, 2); and it alters hepatic
drug metabolism (5). Besides its important role in stimulating the acute-phase de-
fense response ofthe host during the infectious event, IL-1 is involved in, and pos-
sibly responsible for, the development of chronic inflammatory conditions such as
rheumatic diseases and degenerative arthropathies, including rheumatoid arthritis
(6, 7).
On the other hand, IL-1 appears to play a key role in the regulation of immune
responses. Indeed, IL-1 participates in antigen-induced T cell activation and clonal
expansion by triggering IL-2 and IL-4 production and IL-2-R expression (8-10).
In addition, IL-1 is one ofthefactors involved in B cell differentiation and prolifera-
tion (11-13) and it has hematopoietic activity for the earliest precursors in the bone
marrow (14). Possibly as a consequence ofthese stimulatory effects, the in vivo ad-
ministration ofIL-1 can enhance the immune response to different antigens (15-18)
and it can protect the host from lethal challenges with microorganisms (19, 20) or
tumors (21), and from lethal radiation damage (22).
Thus, IL-1 is now considered as a potential candidate for the innovativebiophar-
macology foreseen for the next decade. With the aim of better defining its clinical
use, several attempts have been directed at the identification ofminimalbiologically
active sites ofIL-1, which may be responsible for individual effects, among the mul-
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tiple activities ascribed to IL-1 (23-28). Indeed, a nine residue-long synthetic pep-
tide, corresponding to the highly hydrophylic fragment 163-171 of human IL-10
(VQGEESNDK), was observed to mimic some ofthe immunostimulatory activities
ofthe entire IL-1 molecule, while being nonpyrogenic and unable to stimulate pros-
taglandin production by in vitro cultured fibroblasts (17, 18, 26).
This prompted us to further investigate the potential therapeutic applications of
the 163-171 peptide. In the present report, the in vivo activities of the synthetic
nonapeptide have been examined in a variety of experimental systems. The IL-10
fragment shows immunostimulatory, immunorestorative, antitumoral, and radio-
protective capacities comparable, in several instances, to those of the entire protein.
On the other hand, the same peptide could not reproduce any of the inflammation-
related and toxic in vivo effects shown by IL-1R .
Materials and Methods
Animals.
￿
C3H/Hej mice were obtained from the The Jackson Laboratory (Bar Harbor,
ME) or from Bomholtgaard (Ry, Denmark). C3H/HeN, BALB/c, and CD-1 mice were pur-
chased from Charles River Breeding Laboratories (Calco, Italy). Homozygous nu/nu and het-
erozygous nu/+ mice (genetic background BALB/c) were provided by Bomholtgaard. Hy-
brid (C57BL/10 x DBA/2) F, mice (B10D2F,) were bred in the animal facilities of ENEA
(Roma, Italy). Mice of both sexes were used between 6 and 12 wk of age, unless otherwise
indicated.
IL-1 and Synthetic Peptides.
￿
Different preparations of human rIL-1p were used throughout
these studies with superimposable results. Fragment 112-269, expressed in Escherichia coli and
prepared as described elsewhere (3), was kindly provided by Dr. C . A. Dinarello, Tufts Univer-
sity, Boston, MA. The mature recombinant fragment 117-269, expressed in E. coli, was ei-
ther obtained from Biogen (Geneva, Switzerland) or produced at Sclavo (Siena, Italy). All
preparations, purified to apparent homogeneity, had a specific activity of 1-2 x 10' half-
maximal units/mg protein (corresponding to 1 .75-3.5 x 10'4 U/mole) in the murine thymo-
cyte costimulation assay. Endotoxin contamination was measured in the two 117-269 prepa-
rations with the LAL chromogenic assay (M. A. Bioproducts, Walkersville, MD) and found
to be <2.0 pg/ug IL-1. In selected experiments, two other IL-1 were used with comparable
results: a highly purified preparation ofnatural monocyte-derived IL-1 (mostlya form; gener-
ously provided by C. A. Dinarello), and human rIL-la (mature fragment 113-271, expressed
in E. coli, sp act 2 x 10' U/mg; a kind gift of Dr. P. T. Lomedico, Hoffmann-La Roche,
Inc., Nutley, NJ).
The 163-171 peptide of human IL-10 (VQGEESNDK, mol mass 1 kD) was synthesized
by the solid-phase method and purified by HPLC as described (26). Two salts of the peptide,
163-171 trifluoroacetate (163-171 -TFA)' and 163-171 hydrochloride (163-171-HCl) were
provided by Novabiochem (Laufelfingen, Switzerland). The 163-171 -TFA salt was estimated
to contain one-half the equivalent of TEA/peptide mole. Transformations of the TEA salt
into HCl salt and vice-versa were performed by ion-exchange chromatography on Amberlite
IRA 401 (Cl) resin (BDH Italia, Milan, Italy).
Two other nonapeptides, LKDDKPTLQ (fragment 189-197 of human IL-113) and FRK-
DMDKVE (fragment 166-174 ofhuman chorionic somatomammotropin, hCS), corresponding
to highly hydrophylic moieties ofthe proteins, were also synthesized by the solid-phase method.
All peptide preparations were found to be free of endotoxin contamination by the LAL
chromogenic assay.
Assaysfor In Vivo Immunostimulation.
￿
Determination of specific antibody-producing cells
(PFC) in the spleen of mice was performed as previously described in detail (17). Briefly,
mice received a single antigen inoculum (SRBC, 1-2 x 108/mouse i. v. ; or pneumococcal
' Abbreviations used in this paper: WS, human chorionic somatomammotropin; HRBC, horse red blood
cells; SAA, serum amyloid A; TFA, trifluoroacetate.BORASCHI ET AL.
￿
677
polysaccharide type III, SIII, 0.5 ug/mouse i. p.) or two SRBC inocula 10 d apart (secondary
response). At the time of the antigenic challenge, different doses ofIL-1 or ofpeptide prepara-
tions were administered to the animals either intravenously, intraperitoneally, or subcutane-
ously. The numbers of specific PFC in the spleen of mice were determined either 4 d (re-
sponse to SRBC) or 5 d (response to SIII) later by the Cunningham and Szenberg slide
technique (29).
Helper T cell activity was titrated in the spleen of carrier (horse RBC [HRBC])-primed
mice as previously described (30). Briefly, mice received an inoculum of 2 x 105 HRBC i.v.
and an s.c. injection of either IL-1 or peptide. After 4 d, graded numbers ofcarrier-primed
spleen cells (5-20 x 104 cells/culture) were cultured with 106 spleen cells from untreated mice
and 2 x 105 TNP-HRBC. The antiTNP-specific PFC response was evaluated in the cul-
tures after 4-5 d by the slide technique. Only PFC numbers of cultures receiving 20 x 104
carrier-primed spleen cells are reported in the results.
Radioprotection.
￿
24 h after inoculation with saline, IL-1p, or the 163-171 peptide, groups
of 20 mice were lethally irradiated in a Lucite irradiation chamber with an x-ray dose of 850
rad (dose rate 138.7 rad/min in air) with an x-ray machine (Stabilipan, Siemens Italia, Milan,
Italy), operated at 250 kV, 15 mA, 0 .5 mm Cu filtration, focus distance 50 cm. Survival was
followed for >5 mo, although no further deaths were observed beyond the 27th day after ir-
radiation. Percentage of surviving mice and mean survival time of mice that eventually died
were evaluated.
Tumor Rejection.
￿
BALB/c mice were challenged subcutaneously in the left inguinal region
with 10' cells of the poorly immunogenic syngeneic tumor CE-2 (31). Starting 4 h after tumor
challenge, mice received in the peritumoral area 10 daily subcutaneous injections of 0.4 ml
HBSS alone, or containing IL-1p, the 163-171 peptide of IL-1(3, or the 166-174 peptide of
hCS. The incidence and growth of tumors were recorded twice weekly and the neoplastic
masses were measured with calipers in the two perpendicular diameters. The intervals (in
days) between challenge and the observation of tumors larger than 4 and 12 mm were re-
garded as the latency and survival time, respectively. Mice were then killed for humane reasons
(32).
Fever.
￿
Increase in basal temperature ofendotoxin-resistant C3H/HeJ mice was measured
as previously described (26, 33) . Mice were kept at room temperature for 1 h before intrave-
nous injection of saline, IL-1, or the peptide. Rectal temperature was monitored every 5 min
and expressed as increase compared with the preinjection temperature (AT').
Biochemical Determinations.
￿
Serum iron was determined 4 h after intravenous treatments,
with a commercially available kit (Boehringer-Mannheim, Mannheim, Federal Republic of
Germany).
Fibrinogen was measured in EDTA-treated plasma obtained 24 h after intravenous treat-
ments by the heat-turbidity method of Wycoff (34).
Serum amyloid A (SAA) was evaluated in serum samples by solid-phase competitive RIA
(35). Briefly, 25-pl serum samples were heated at 60°C in tightly capped tubes for 1 h, then
diluted with 1 ml casein barbital buffer. Triplicate 200-gl aliquots ofthe diluted samples were
analyzed by RIA. SAA was expressed as micrograms of amyloid A equivalents/milliliter.
Serum levels of corticosterone and insulin were determined by RIA, and serum levels of
glucose by the hexokinase enzymatic method, as described elsewhere (3, 4). Determinations
were performed 2-4 h after intraperitoneal or subcutaneous treatments.
Cytochrome P450-dependent ethoxycoumarin-o-deethylase (ED) activity was assessed in
liver homogenates of mice treated 24 h earlier, according to Greenlee and Poland (36).
Shock in AdrenalectomizedMice.
￿
Determination of IL-1-induced shock and death in adrenalec-
tomized mice was performed as previously described (37). Adrenalectomy was performed
under ether anesthesia 10 d before treatment. Adrenalectomized mice were given 1% wt/vol
sodium chloride in the drinking water. Mice received an intravenous inoculum of sterile
pyrogen-free saline alone or containing IL-1 or the peptide, then monitored for 7 d. All deaths
occurred within 24 h.
Statistical Analysis.
￿
Data (except those relating to survival) are calculated as the mean ±
SEM of values of 3-10 individual animals tested within single representative experiments,
or ofvalues from different experiments. Statistical significance was calculated by Student's t test.678
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For the evaluation of helper T cell activity, statistical significance was determined by a
two-tailed Student's t test on the regression coefficients of straight lines forced through the
origin by the least squares method (38) of the titration curves.
Tumor inhibition experiments were performed independently at least three times. Those
giving homogeneous results, as determined by the Snedecor and Irwin test (39), were cumu-
lated. Thesignificance ofdifferences in tumortakeswas determined by Fisher's exact method,
while those in latency and survival time were determined by a one-tailed Student's t test.
Survival of treated versus control animals in the experiments of radioprotection and shock
afteradrenalectomywas evaluatedby Fisher's exact method. Differences in the mean survival
time of lethally irradiated mice were determined by analysis of variance.
Results
Intravenous administration of the synthetic fragment 163-171 of human IL-1(3
together with the Tdependent antigen SRBC could greatly increase the primary
immune response against the antigen, measured as thenumber ofspecific antibody-
producing cells (PFC) in the spleen 4 d after immunization (Fig. 1). Two prepara-
tions of the peptide were assayed and compared with the mature human rIL-1(3.
The immunoenhancing effects of human rIL-1R and of the 163-171-HCI prepara-
tion were qualitatively and quantitatively similar. In contrast, 104-106-fold higher
doses of the 163-171 TFA peptide preparation were needed to attain maximal im-
munostimulatory effects. The discrepancy between optimallyactive doses of thetwo
peptide preparations could be fully ascribed to the presence or absence of TFA. In
fact, conversion of the TFA salt of the peptide into HCl salt could significantly in-
crease its adjuvant activity (Fig. 2, left). Accordingly, conversion ofthe HCl salt into
TFA salt dramatically lowered the immunostimulatory effectiveness of the peptide
(Fig. 2, middle). Finally, addition of free TFA to the 163-171-HCl preparation or to
human rIL-1R could equally decrease their adjuvant effects (Fig. 2, right). TFA was
found to interfere with peptide activities in vivo only by increasing the optimal ac-
tive dosage by several orders of magnitude, without any qualitative effect on the re-
sponse obtained (data not shown).
Besidesitseffect on the primaryresponse to aT -dependent antigen, theimmunoen-
hancing activity of the synthetic IL-1(3 peptide, as compared with the entire mole-
cule, was also evident in the secondary response to SRBC and in the response to
the Tindependent antigen SIII (Table I). In contrast, neither the nonapeptide nor
human rIL-1R could affect the number of spontaneous PFC anti-SRBC in thespleen
of nonimmunized mice (Table I).
Administration of the synthetic IL-1R fragment could also restore or significantly
augment the immune response in immunodepressed animals (Table II). In most
ofthe immunosuppressiveconditions examined (treatment with cyclophosphamide,
300
0
U
200
w
a
100
.15 .12 -9 -6 .3
log MO"
FIGURE 1.
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In vivo stimulation of the primaryresponse to SRBC
by human rIL-1(3 (p), the 163-171 .TFA peptide (A), and the
163-171 -HCl peptide (*). Increasing doses ofthedifferentmole-
cules were inoculated intravenously together with the antigen
SRBC. TheSRBC-specific PFC response in thespleen wasevalu-
ated 4 dlater andexpressed as percent of the control response of
animalsreceiving the antigen alone. Data arethemean values from
45 separate experiments. SEM neverexceeded 1070 and arethus
not shown. Mean antiSRBC PFC/spleen of control animals in
the experiments considered were 37,926 ± 840.FIGURE 2.
￿
Comparison ofthe immuno-
stimulatory activity of the 163-171 .TFA
peptide with that of the 163-171 -HClpep-
tide. The primary anti-SRBC PFC re-
sponse was evaluated in mice immunized
with SRBC and inoculated intravenously
with increasing doses ofthe adjuvant pep-
tides. Left, 163-171 -TEApeptide (A); 163
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(*). Middle: 163-171 . HCl peptide (*);
163-171-HC1 transformed into 163-171 TFA
(A). Right: 163-171 HCl (* ); 163-171-HCl with addition of one-half equivalent of TEA (A); human
rIL-10 (p); human rIL-10 with addition of one-half equivalent of TEA (0). Results are from single
experiments representative of six performed and are expressed as percent of the control response of
animals receiving the antigen alone. SEM never exceeded 10% and are thus not shown. Mean anti-
SRBC PFC/spleen of control animals in the experiments considered were 35,709 ± 1,596.
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aging, sublethal irradiation), the immune response of suppressed animals could be
restored by inoculation of the nonapeptide to levels comparable to those of the un-
treated immunocompetent controls. However, in thecase of genetically athymic nu/nu
mice, full restoration of the immune response could not be achieved by administra-
TABLE I
Immunostimulatory Activity of the 163-171 Fragment on Spontaneous, Primary, and Secondary
Response In Vivo
Results are the mean ofdata from 2 to 27 separate experiments, each including three individual mice per
experimental group. Both human rIL-1(i and the 163-171 peptide were inoculated 4-5 d before assay,
at previously determined optimal doses, either intravenously or intraperitoneally. Either C3H/HeN or
C3H/HeJ mice were used, with identical results.
Direct PFC anti-SRBC were measured in the spleen of nonimmunized C3H/HeJ male mice 4 days after
administration of hu rIL-1(9 (6 x 10-12 moles/kg i.p. or 10-13 moles/kg i.v.) or the 163-171 TFA pep-
tide (10-4 moles/kg i.p. or 10-8 moles/kg i.v.).
$ Mice received either saline or human rIL-lp (0 .1-3 x 10-14 moles/kg) or the 163-171 .HC1 fragment
(10-14-10-12 moles/kg) i .v. together with the antigen. Splenic PFC anti-SRBC were measured 4 dlater.
In other experiments, the 163-171 .TFA peptide wasactive at 10-8-10-6 moles/kg by the same route. When
administered i.p., human rIL-1(i was active at 0.6-6 x 10-12 moles/kg, the 163-171 -TFA peptide at 0.3-1
x
￿
10-4 moles/kg, and the 163-171 -HCl salt at 10-10-10-6 moles/kg.
5 The anti-SIII Splenic PFC response was determined 5 d after antigen administration and inoculation of
saline, human rIL-1(3 (0.5-1 x 10-12 moles/kg i.p .) or 163-171-HC1 peptide (10-13 moles/kg i.v.). In
other experiments, the 163-171. TFA salt was active at 10-4 moles/kg when administered i.p.
II Direct and total (direct plus IgG) PFC anti-SRBC were measured in the spleen of C3H/HeN mice im-
munized twice with SRBC, 4 d after the last antigen inoculum. Saline, human rIL-10 (0.3-2 x 10-12
moles/kg i.p.), or the 163-171 . HC1 peptide (10-11 -10-9 moles/kg i.v.) were administered with the second
antigen challenge. In other experiments, the 163-171 TFA fragment was active at 10- 7 moles/kg i.v. and
at 10-4 moles/kg i .p.
p < 0.01 vs. saline control .
'" NT, not tested.
BORASCHI ET AL.
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Immune
response Antigen PFC
Specific PFC/spleen (percent control) of mice treated with:
Saline IL-1(i 163-171
Spontaneous SRBC` Direct 203 (100 .0) 227 (112.1) 194 (95.8)
Primary SRBC1 Direct 38,357 (100.0) 89,317 (232.9)1 89,699 (233.9)1
sills Direct 1,070 (100 .0) 3,500 (327.3)1 3,116 (291.4)1
Secondary SRBC11 Total 32,160 (100 .0) 69,957 (217.5)1 70,480 (219.2)1
Direct 9,397 (100 .0) NT" 16,458 (175.1)1
IgG 24,722 (100 .0) NT 54,021 (218.5)1680
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TABLE II
Immmunorestoration by the 163-171 Fragment In Vivo in Immunodepressed Mice
Results are the mean of data from two to five separate experiments. Both human rIL-1(3
and the 163-171 peptide were inoculated 4 d before assay, at previously determined optimal
doses, either intravenously or subcutaneously.
C3H/HeN male mice received 50 mg/kg i.p. of cyclophosphamide 2 d before inoculation
of SRBC . The 163-171-HCl fragment (10- 11 moles/kg) or human rIL-1(3 (0 .3 x 10-13
moles/kg) were injected intravenously together with the antigen. Splenic PFC anti-SRBC
were measured 4 d after. The 163-171 TFA fragment was active at 5 x 10-5 moles/kg i .p.
in the same system.
$ Splenic PFC anti-SRBC were measured in heterozygous (nu/+) and athymic (nu/nu) BALB/c
male mice 4 d after antigen administration. Human rIL-1(i (0.6 x 10-14 moles/kg i.v. or
0.6 x 10-t1 moles/kg i.p.) and the 163-171-HCl peptide (10-11-10-7 males/kg i.v.) were
inoculated together with the antigen. In other experiments, the 163-171 TFA fragment was
active at 10` 7 moles/kg i.v. and at 10-5-10-4 moles/kg i.p.
s Anti-TNP PFC were measured after 4-5 d of culture of 106 normal spleen cells with TNP-
HRBC and 20 x 104 spleen cells from young (3 mo) or old (15 mo) Bl0D2Ft male mice
inoculated 4 d earlier with HRBC intravenously and with human rIL-1 (3 (10- 12 moles/kg)
or with the 163-171 .TFA synthetic fragment (10 -4 moles/kg) s.c. Mean background anti-
TNP response of 106 normal spleen cells cultured with TNP-HRBC without added helper
cells was of 112 PFC/culture.
II Anti-TNP PFC were measured as described above. BIOD2Fi male mice were either left un-
treated or irradiated with 200 rad (x-ray irradiation, Stabilipan) 7 d before intravenous priming
with HRBC and subcutaneous administration of human rIL-1R (10-12 moles/kg) or the
163-171 TFA peptide (10-4 moles/kg). Mean background anti-TNP response in the absence
of added helper cells was of 38 PFC/culture.
p < 0 .01 vs. saline control.
tion of either the synthetic fragment or human rIL-1R, although ahighly significant
increase in the response could nevertheless be observed (Table II).
Finally, survival of mice undergoing lethal irradiation and tumor engraftment was
significantly improved by the 163-171 fragment of human IL-1(i, as well as by the
entire protein (Table 111). In fact, 50 and 75% of mice receiving IL-la and the
nonapeptide, respectively, 24 h before 850 rad irradiation were still alive after>120
d, whereas all control mice died within 16 d. Similarly, significant survival after a
lethal tumor challenge was induced in mice by treatment with either the 163-171
fragment or IL-1Q, in addition to increasing both the latency time and the survival
time ofmice developing the tumor (Table III). In another set of experiments, it was
found that both IL-1 0 and 163-171 peptide are nontoxic in vitro to proliferatingtumor
Immunosuppressive
condition
Response
measured
Response after treatment with:
Saline IL-1(3 163-171
Immunosuppressive drugs' PFC/spleen
Control 42,170 84,3241 78,4421
Cyclophosphamide 26,779 75,3351 78,525'
Genetic deficiencyl PFC/spleen
nu/+ 38,038 115,2321 121,6651
nu/nu 693 2,6601 3,4801
Ages PFC/culture
Young 633 812 1,3341
Old 162 2271 501 ,
Irradiationll PFC/culture
Control 278 317 4731
200 rad 126 3141 4851BORASCHI ET AL.
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TABLE III
Protection by the 163-171 Fragment from Lethal Irradiation and Tumor Graft
` B10132F1 female mice (2 mo old) received an intraperitoneal inoculum of saline alone or
containing human rIL-1(3 (0.6 x 10-9 moles/kg) or the 163-171-TFA peptide (10-5
moles/kg) 20 h before irradiation with 850 rad. 40 of40 saline-injected mice were dead 16 d
after irradiation. Mice were followed for up to 5 mo, with no further deaths observed 27 d
after irradiation .
$ BALB/c female mice (8 wk old) were engrafted subcutaneously with 103 cells of the poorly
immunogenic syngeneic tumor CE-2 . Beginning 4 h later, mice received 10 daily injections
ofsaline (HBSS), human rIL-1(i (0.6 x 10-16 moles/mouse/day), or 163-171 -HCl peptide
(10-15 moles/mouse/day) subcutaneously in the peritumoral area. Mice receiving the 166-174
peptide of hCS with the same schedule of treatment did not differ from saline-treated con-
trols (surviving/total, 0/20) (data not shown).
S p < 0.05 vs. saline control.
cells and that the capacity to reject the tumor challenge rests fully on their ability to
recruithostimmunoreactivity (Forni, G., T Musso, D. Boraschi, C.Jemma, A. Tag-
liabue, and M. Giovarelli, submitted for publication).
IncontrasttothehighIL-1-likeimmunoenhancing andprotective effects, the 163-171
fragment could not mimic any ofthe inflammation-related activities ofhuman IL-
10 measured in vivo. In fact, thenonapeptide did not induce arise in the basaltem-
perature of C3H/HeJ mice (Table IV). In parallel to its lack of pyrogenicity, the
nonapeptidecould not provoke the acute phase-associated changes induced by IL-1
such as hypoferremia, decrease ofblood levels of fibrinogen and glucose, decrease
ofhepatic P450-dependent metabolism, increaseofserumlevels ofSAA, corticosterone,
andinsulin(Table IV). Possibly as aconsequence ofthe lackofinflammatory effects
invivo, the 163-171 fragment could not induce shock anddeathin adrenalectomized
mice, in contrast to the potent toxic effect of the entire IL-1 molecule in the same
system (Table IV). The lack ofinflammatory effects ofthe 163-171 peptide was evi-
dent in each experimental system over a wide range ofdoses, exceeding up to 106-
fold the optimal immunostimulatory doses (data not shown). In addition, two other
synthetic nonapeptides, corresponding to highly hydrophylic sequences ofhuman
IL-10 (LKDDKPTLQ, position 189-197) and of hCS (FRKDMDKVE, position
166-174) did not show either immunostimulatory or inflammatory activities when
tested in parallel to the 163-171 fragment of IL-10 (data not shown).
Discussion
Potentiation and/or restoration ofthe host immune defenses has been attempted
for many years in the therapyofseveral diseases, includingimmunodeficiencies, in-
fections, and cancer, first by the use ofbacterial immunomodulators and more re-
In vivo
treatment Alive/total
Survival
Percent surviving
Latency time
t SEM
Survival time
t SEM
Radioprotection'
Saline 0/40 0 - 10.0 t 0.5
IL-10 10/20 505 - 14.8 t 1 .7S
163-171 15/20 75S - 14,2 t 3.2
Tumor rejection$
Saline 1/20 5 14.5 t 2 .1 25.6 t 3.2
IL-1(i 12/20 60S 25.2 t 6.3S 36,8 t 2.75
163-171 11/20 55S 21 .0 t 3.2S 35.9 t 3.05682
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TABLE IV
Lack of Inflammatory and Toxic Effects by the 163-171 Peptide of Human IL-1P in vivo
(mortality)
￿
0/10 (0%)
￿
7/10 (70%)§§
￿
0/5 (0%)
Results are the mean ± SEM of values from 4 to 10 mice tested within single representative
experiments.
* Increase ofbasal temperature was measured in C3H/HeJ male mice 25 min after intravenous
inoculation of 0 .6 x 10- 11 moles/kg human ILAR or 3-6 x 10-4 moles/kg 163-171-TFA
peptide.
l Serum iron levels were evaluated in CD-1 male mice 4 h after intravenous inoculation of
1 .7 x 10- `t moles/kg human rIL-la or 3 x 10-6 moles/kg 163-171 .HCI peptide. In other
experiments, human rIL-1(3 was found to have the same qualitative and quantitative effects
as human rIL-lot (not shown).
Fibrinogen was measured in plasma of CD-1 male mice 24 h after intravenous injection of
1 .7 x 10-9 moles/kg human rIL-la or 3 x 10-6 moles/kg 163-171 .HC1 fragment. In other
experiments, human rIL-10 was found to be active in the same dose range as human rIL-let,
and the 163-171TFA peptide did not show any activity at doses up to 10-4 moles/kg.
II Serum levels ofglucose, corticosterone, and insulin were determined in C3H/HeJ male mice
2 h after administration of human rIL-10 (10- " to 2 x 10-to moles/kg) or of the
163-171 .TFA peptide (2 to 4 x 10-4 moles/kg) i.p. or s.c.
SAA was measured in serum of CD-1 male mice that received 6 h earlier an inoculum of
human rIL-10 (1 .7 x 10- 12 moles/kg) or of the 163-171-HCI peptide (3 x 10-6 moles/kg)
i.v.
" " Cytochrome P450-dependent ED activity was evaluated in the liver of CD-1 male mice
24 h after administration ofhuman rIL-la (1 .7 x 10-9 moles/kg) or of the 163-171 HCI
fragment (3 x 10-6 moles/kg) i.v. In other experiments, human rIL-10 was found to be
as active as human rIL-la, and the 163-171-TFA peptide did not have activity at doses
up to 10-4 moles/kg.
l l
￿
Shock in adrenalectomized CD-1 male mice was assessed as mortality (dead/total; percent
dead animals) after administration of human rIL-1(3 (10-9 moles/kg) or of the
163-171 .HCl peptide (3 x 10"a moles/kg) i.v. All deaths occurred within 24 h from IL-1
inoculum.
§§ p < 0 .01 vs. saline control.
cently with synthetic bacterial moieties (40). The increasing knowledge of the bi-
ology ofthe soluble factors involved in cell-to-cellcommunication has clearly indicated
that most of the activities of the classical immunomodulators could be mediated
through the induction ofinterleukins, interferons, and growth factors. Thesecytokines,
now available in large quantities by means of recombinant DNA techniques, are
thus beginning to be tested directly in clinical trials. This new generation of im-
munomodulators represents an improvement in comparison to the previous agents,
such as whole bacteria (bacille Calmette-Guerin and Corynebacteriumparvum) orfrag-
ments (levamisole and pyran copolymer). However, the variety ofbiological effects
ofeachcytokine makesthe appropriate clinical exploitationofthesefactors stilldifficult.
Response
measured
Response after treatment
Saline IL-1
with:
163-171
Fever* (AT') 0.15 ± 0.05 1 .25 ± 0.25§4 0.15 ± 0.05
Blood levels of:
Ironl (ug/ml) 1 .27 ± 0.14 0.77 t 0.10§§ 1 .12 f 0.10
Fibrinogens (mg/ml) 1 .19 ± 0.17 2.20 ± 0.08§§ 1 .35 ± 0.21
Glucosell (mg/dl) 110.00 ± 5 .37 69.01 ± 2.63§§ 122.90 t 3 .48
SAAB (ug/ml) 3 .48 ± 1 .23 100.00 ± 39.56§§ 2.50 ± 0.65
Corticosteronell (4g/100 ml) 3.90 ± 1 .36 30.90 ± 2.14§§ 2.57 ± 0.40
Insulinll (pg/ml) 760.0 ± 103 .7 2,033.0 ± 377.0§§ 832 .0 ± 61 .9
Hepatic ED** (nmoles/min/g) 18.59 ± 1 .35 12.16 ± 0.63§§ 16.03 ± 1 .10
Shock after adrenalectomyllBORASCHI ET AL.
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A further step towards a less empiric immunotherapy may be represented by the
identification, within the cytokine molecules, of active sites responsible for certain
biological functions. This information is expected to provide the basis for thedesign
of cytokine analogs that are more suitable for pharmaceutical use in terms of sta-
bility, biodisposition, and affinity for the receptor.
An example for the feasibility of this approach has come from studies directed
to elucidate the relationship between structure and function ofIL-1 (17, 26). A short
synthetic peptide (VQGEESNDK, corresponding to thefragment 163-171 of human
IL-1R), was chosen as possible active site on the basis of its predicted exposure on
the surface of the IL-1a protein molecule. Upon a first analysis of its biological ac-
tivities, thenonapeptidewas shown to mimic several oftheimmunostimulatory effects
of IL-1 in vitro and in vivo, although it was not pyrogenic, nor could it induce PGE2
synthesis in cultured human fibroblasts. This fragment could thus represent one
of the active sites of human IL-1R, responsible for its immunomodulatory effects.
However, peptide doses up to five to six orders of magnitude higher than those of
IL-1 were necessaryto reach the biological effect of the entire molecule. The holistic
interpretation that other fragments of the molecule are necessary to determine the
extremely high activity of IL-1 was proposed to explain the differences in dosage
(26). In contrast to this, it was observed in this study that after transformation of
the peptide from the TFA salt to the HCl, the immunostimulatory activity in vivo
was increased up to 106-fold. On the other hand, in vivo administration of IL-1 to-
gether with free TFA at a concentration equivalent to that contained in the peptide
preparation resulted in a strong reductionof the IL-1 adjuvant activity. This demon-
strates that, at least as far as adjuvanticity is concerned, the peptide and the entire
IL-1 areequivalent also on a quantitative basis. Thus, thehypothesis that the 163-171
fragment of IL-1 is theactive site for immunomodulation gains furtherexperimental
support. Conversely, the result that TFA is somehow able to reduce IL-1 functions
constitutes a warning that false negative results are likely to be obtained with syn-
thetic peptides of IL-1 obtained by classic procedures, since TFA is a reagentwidely
used in peptide synthesis and purification.
The analysis of the in vivo immunomodulatory capacity of the 163-171 peptide
was extended to the immunocompromised host. The nonapeptide could exert an
adjuvant activity at least equivalent to that ofthe entire IL-1 in animals immunolog-
ically depressed by chemotherapy or irradiation as well as in genetically im-
munodeficient or aged mice. It can therefore be concluded that the nonapeptide
is able to restore depressed immunological functions.
The observation that the 163-171 peptide was able to restore immune reactivities
aftersublethal irradiation, together with previous results ofother authors showingthe
radioprotective capacity of IL-1 (22), prompted us to investigate whether thenonapep-
tide could also share with IL-1 this latter activity. Indeed, this wasthe case. Moreover,
treatment with the 163-171 peptide can also result in significant protection against
atransplanted tumor. In fact, repeated local injection of small amounts ofthe 163-171
peptide at the tumor challenge site reduces tumor takes of a poorly immunogenic
syngeneic sarcoma. Latency and survival times of those peptide-treated mice that
eventually developtumors areextended in comparison to controls. Here, again, peptide
activity is equivalent to that of IL-1. Data not reported here show that the tumor
growth inhibition is due to the ability of the peptide to trigger and recruit locally684
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the host immunereactivity, with no direct toxicity ontumor cells(Form, G., T. Musso,
D. Boraschi, C. Jemma, A. Tagliabue, and M. Giovarelli, submitted forpublication).
Incontrasttoits significant effect on theimmuneresponse, the synthetic nonapeptide
did not show any of several acute-phase and inflammation-related changes caused
by IL-1, when injected in vivo at doses up to 106-fold higher than the optimal im-
munostimulatory inocula. Indeed, the 163-171 fragmentwas nonpyrogenic and failed
to induce the typical decrease ofplasma iron and fibrinogen, and the increase of
the acute-phase protein SAA. Accordingly, the synthetic peptide could not induce
the alterations in glucose homeostasis (decrease in blood levels ofglucose in parallel
to increase ofinsulin) that occur during sepsis and other inflammatory conditions,
and that can be induced by IL-1(3 . Administration ofthe peptide was also unable
to increase the serumlevels ofcorticosterone, a highly immunosuppressivehormone
involved in protein catabolism that is augmented during certain infectious diseases
and in response to IL-1 (2, 3). Finally, at variance with the significant effect ofIL-1
(5), the 163-171 fragment did not depress the cytochrome P450-dependent hepatic
drug metabolism, an event induced by several inflammatory stimuli.
These results confer a broaderbiological significance to thefinding that the 163-171
peptide is an immunostimulatory moiety of IL-10 that is devoid of the inflamma-
tory and toxic effects of the entire protein. Thus, the potential clinical relevance
of this molecule is further stressed.
As a corollary to this conclusion, it can be suggested that the ability to activate
the immune response, which may in turn affect hematopoiesis by means of induc-
tion ofsoluble growth factors, may be sufficient by itself to induce radioprotection.
Therefore, activation ofinflammatory pathways would notbenecessarytothe recovery
from radiation damage. Taken together, these data indicate that a further step to-
wards a more rational immunotherapy is possible, by searching for active domains
within interleukins.
Summary
The synthetic nonapeptideVQGEESNDK, correspondingto the fragment 163-171
of human IL-1(3, showed in vivo immunomodulatory capacities qualitatively and
quantitatively comparable to those ofthe mature human IL-10 protein. In fact, both
IL-10 and the 163-171 fragment stimulated the immune response ofnormal mice
andrestored immune reactivities ofimmunocompromised animals. In addition, the
synthetic IL-1 peptidewas asefficient as the entire protein in inducing tumor rejec-
tion and radioprotection. On the other hand, the 163-171 fragment did not cause
any of several inflammation-associated metabolic changes inducible by the whole
IL-10 molecule in vivo: hypoferremia, hypoglycemia, hyperinsulinemia, increase in
circulatingcorticosterone, SAAandfibrinogen, decrease in hepatic drug-metabolizing
enzymes. Furthermore, at variance with IL-1(3, the 163-171 peptide did not show
the toxic effects causing shock and death in adrenalectomized mice.
Thus, these results confirm our previous in vitro observations that functional do-
mains are identifiable within the multipotent cytokine IL-1(3, and demonstrate the
biological relevance ofthis finding in a variety ofin vivo systems. The identification
of a selectively active fragment of a cytokine may thus represent a significant step
towards a better directed and more rational immunotherapeutic approach.
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